Lupin , a prominent player in the pharmaceutical industry, recently completed a significant block trade on the National Stock Exchange (NSE), demonstrating robust market activity in its shares.

Block Trade Details

The block trade, executed on the NSE, involved approximately 203,861 shares of Lupin. The transaction was valued at Rs. 39.99 crores, with each share priced at Rs. 1,961.70. This substantial trade highlights the continued interest in Lupin's stock among institutional investors and large market participants.

Market Implications

Block trades of this magnitude often indicate strategic moves by large investors or institutions. While the specific parties involved in this transaction have not been disclosed, such trades can sometimes signal shifting investor sentiments or portfolio realignments.

Company Overview

Lupin, headquartered in Mumbai, is a multinational pharmaceutical company known for its wide range of generic and branded formulations, as well as active pharmaceutical ingredients (APIs). The company has a strong presence in various therapeutic segments and markets globally.

Recent Corporate Developments

In a separate corporate update, Lupin's Board of Directors has approved the re-appointment of Mr. Mark D. McDade as an Independent Director for a second term. This decision, subject to shareholder approval, extends Mr. McDade's tenure from January 28, 2026, to January 27, 2031.

Mr. McDade brings over four decades of experience in the biopharmaceutical industry to Lupin's board. His expertise spans areas such as:

• Corporate Governance
• Leadership & General Management
• Healthcare Pharma/Science & Technology
• Manufacturing, Quality & Supply Chain
• Risk Management
• ESG
• Information Technology
• Mergers & Acquisitions

This reappointment reflects Lupin's commitment to maintaining strong corporate governance and leveraging experienced leadership to guide its future strategies and operations.

The recent block trade, coupled with the board's decision to retain key leadership, underscores Lupin's active market presence and its focus on long-term strategic planning in the competitive pharmaceutical landscape.

Lupin Limited , a global pharmaceutical leader, has announced the launch of Bosentan Tablets for Oral Suspension, 32 mg, in the United States market. This strategic move follows the approval received by Lupin's alliance partner, NATCO Pharma Limited, from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application.

Exclusive First-to-File Status

NATCO Pharma Limited holds the exclusive first-to-file status for this product, granting them a significant 180-day generic drug exclusivity period. This advantage positions Lupin and NATCO favorably in the competitive pharmaceutical market.

Product Details and Indications

The newly launched Bosentan Tablets for Oral Suspension, 32 mg, are bioequivalent to Tracleer® Tablets for Oral Suspension, manufactured by Actelion Pharmaceuticals US, Inc. These tablets are specifically indicated for the treatment of pulmonary arterial hypertension (PAH) in pediatric patients aged 3 years and older with idiopathic or congenital PAH.

The primary goal of this treatment is to improve pulmonary vascular resistance (PVR), which is expected to result in enhanced exercise ability for patients. This launch addresses a critical need in pediatric PAH treatment, potentially improving the quality of life for young patients suffering from this condition.

Market Potential

According to IQVIA data, Bosentan Tablets (RLD Tracleer®) had estimated annual sales of USD 10.00 million in the U.S. market. This figure underscores the potential market opportunity for Lupin and NATCO with their generic version of the drug.

About Lupin Limited

Lupin Limited, headquartered in Mumbai, India, is a prominent player in the global pharmaceutical industry. The company's products are distributed in over 100 markets worldwide. Lupin specializes in a wide range of pharmaceutical products, including:

• Branded and generic formulations
• Complex generics
• Biotechnology products
• Active pharmaceutical ingredients

With a strong presence in India and the United States, Lupin has established itself as a trusted name among healthcare professionals and consumers across multiple therapy areas, including:

• Respiratory
• Cardiovascular
• Anti-diabetic
• Anti-infective
• Gastrointestinal
• Central nervous system
• Women's health

The company boasts an impressive infrastructure with 15 state-of-the-art manufacturing sites and 7 research centers globally. Lupin's dedicated workforce of over 24,000 professionals contributes to its mission of improving patient health outcomes through various subsidiaries, including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

This latest product launch reinforces Lupin's commitment to expanding its portfolio and addressing critical healthcare needs in the U.S. market, particularly in the area of pediatric pulmonary arterial hypertension treatment.